Johnson & Johnson JNJ
NYSE JNJ
$270.24 +2.87 (+1.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)

Johnson & Johnson (JNJ) posted Liabilities from Discontinued Operations of 3590000000.0 for Q1 2023.

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends

Johnson & Johnson has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 3590000000.0 in Q1 2023.

  • Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 3590000000.0 in Q1 2023, while the trailing twelve-month figure through Jan 2023 was 3590000000.0 (changed N/A YoY) and the FY2023 annual result came in at 3590000000.0, changed N/A from the prior year.
  • Liabilities from Discontinued Operations was little changed at 3590000000.0 in Q1 2023 per JNJ's latest filing.
  • Over five years, Liabilities from Discontinued Operations peaked at 3590000000.0 in Q1 2023 and troughed at 3590000000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Jan 1, 2023 3.59 Bn
Jan 1, 2023 3.59 Bn